Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations.

PloS one - 1 Jan 2014

Yu Chuanjiang, Kancha Rama Krishna, Duyster Justus

Abstract excerpt

FLT3 is the most frequently mutated kinase in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) in the juxta-membrane region constitute the majority of activating FLT3 mutations. Several FLT3 kinase inhibitors were developed and tested in the clinic with significant success. However, recent studies have reported the development of secondary drug resistance in patients treated with FLT3 inhibitors....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to fms-Like Tyrosine Kinase 3
Share to Gene Expression Regulation, Leukemic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Lactams, Macrocyclic

Share to Leukemia, Myeloid, Acute

Share to Protein Stability

Share to Proteolysis

Source

Open in PubMed Open full text

Identifiers

PMID: 24849514
DOI: 10.1371/journal.pone.0097116
PMCID: PMC4029991

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations.PMID 24849514Read ↗

Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy.Semantic proximity Read ↗

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML.Semantic proximity Read ↗

LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.Semantic proximity Read ↗

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.Semantic proximity Read ↗

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategiesSemantic proximity Read ↗

FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Semantic proximity Read ↗

Resistance to targeted therapies: delving into FLT3 and IDH.Semantic proximity Read ↗

A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment.Semantic proximity Read ↗

Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.Semantic proximity Read ↗

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least ResistanceSemantic proximity Read ↗

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.Semantic proximity Read ↗

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.